Core Viewpoint - Centene Corporation reported a mixed performance in its latest earnings report, with adjusted earnings per share beating estimates but showing a decline compared to the previous year, while revenues increased significantly year over year [3][4]. Financial Performance - Centene's Q3 2025 adjusted earnings per share were 50 cents, surpassing the Zacks Consensus Estimate of a loss of 21 cents, but down from $1.62 per share in the prior year [3]. - Revenues increased by 18.2% year over year to $49.7 billion, exceeding the consensus mark by 4.4% [3]. - Premiums totaled $44.1 billion, up 22.2% year over year, driven by higher premiums and expanding membership in the Prescription Drug Plan (PDP) [6]. Revenue Breakdown - Medicaid revenues grew 9% year over year to $23.2 billion, while Medicare revenues surged 66% to $9.4 billion [5]. - Commercial revenues improved by 26% year over year to $11 billion [5]. - Service revenues decreased by 1.5% year over year to $772 million, although it beat estimates [7]. Membership and Costs - Total membership (excluding TRICARE) reached 28 million as of September 30, 2025, an 8% increase year over year [8]. - The health benefits ratio deteriorated to 92.7%, a decline of 350 basis points year over year [9]. - Operating expenses rose 37% year over year to $56.6 billion, driven by higher medical costs, which increased by 27% [9]. Cash Flow and Equity - Centene ended Q3 with cash and cash equivalents of $17.1 billion, up from $14.1 billion at the end of 2024 [11]. - Total stockholders' equity fell to $21 billion from $26.5 billion at the end of 2024 [12]. - The company generated $4.7 billion of net cash from operations in the first nine months of 2025, a significant increase from $741 million a year ago [12]. Share Repurchase - Centene repurchased common shares worth approximately $473 million in the first nine months of 2025 [13]. Market Sentiment and Outlook - There has been a downward trend in estimates, with the consensus estimate shifting down by 42.99% [14]. - Centene holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the coming months [16]. - The stock has a subpar Growth Score of D and a score of A on the value side, placing it in the top 20% for value investment strategy [15].

Core Insights - Centene Corporation (CNC) reported third-quarter 2025 adjusted earnings per share of 50 cents, exceeding the Zacks Consensus Estimate of a loss of 21 cents, but down from $1.62 per share a year ago [1][11] - Revenues increased by 18.2% year over year to $49.7 billion, surpassing the consensus mark by 4.4% [1][11] Revenue Breakdown - Medicaid revenues grew 9% year over year to $23.2 billion, while Medicare revenues surged 66% year over year to $9.4 billion [3] - Commercial revenues improved by 26% year over year to $11 billion [3] - Total premiums reached $44.1 billion, a 22.2% increase year over year, driven by higher premiums and expanding membership in the Prescription Drug Plan (PDP) [4] Membership and Operational Metrics - Total membership (excluding TRICARE) was 28 million as of September 30, 2025, reflecting an 8% year-over-year growth [6] - The health benefits ratio deteriorated to 92.7%, a decline of 350 basis points year over year [7] Cost and Expenses - Operating expenses totaled $56.6 billion, a 37% increase year over year, attributed to higher medical costs, impairment expenses, and selling, general, and administrative expenses [7] - Medical costs alone increased by 27% year over year [7] Financial Position - Centene ended the third quarter with cash and cash equivalents of $17.1 billion, up from $14.1 billion at the end of 2024 [9] - Total assets decreased to $82.1 billion from $82.4 billion at the end of 2024 [9] - Long-term debt decreased to $17.5 billion from $18.4 billion as of December 31, 2024 [9] Shareholder Actions - Centene repurchased common shares worth approximately $473 million in the first nine months of 2025 [12]

Core Insights - Centene Corporation (CNC) reported first-quarter 2025 adjusted earnings per share (EPS) of $2.90, exceeding the Zacks Consensus Estimate by 22.9% and reflecting a 28% year-over-year increase [1] - Revenues increased by 15.4% year over year to $46.6 billion, surpassing the consensus mark by 7.2% [1] Revenue Breakdown - Medicaid revenues grew 4% year over year to $22.3 billion, while Medicare revenues surged 48% year over year to $8.8 billion [3] - Commercial revenues improved 31% year over year to $10.1 billion [3] - Total premiums reached $41.7 billion, a 17.4% year-over-year increase, driven by higher premiums and expanding membership in the Prescription Drug Plan (PDP) [4] Service Revenues and Income - Service revenues decreased by 3.8% year over year to $777 million, although it exceeded the consensus mark [5] - Investment and other income fell 29.9% year over year to $382 million, missing the consensus estimate [5] Membership and Health Benefits Ratio - Total membership was 27.9 million as of March 31, 2025, down 1.7% year over year, missing consensus expectations [6] - Membership in the Commercial business increased significantly by 27.3% year over year [6] - The health benefits ratio (HBR) deteriorated by 40 basis points year over year to 87.5% [6] Financial Performance - Adjusted net earnings rose 18.7% year over year to $1.4 billion [7] - Operating expenses totaled $45.1 billion, a 14.7% year-over-year increase, attributed to higher medical costs and administrative expenses [7] - Adjusted SG&A expense ratio improved by 80 basis points year over year to 7.9% [8] Cash and Debt Position - As of March 31, 2025, cash and cash equivalents were $14.8 billion, a 5.3% increase from the end of 2024 [9] - Total assets increased by 5.6% to $87 billion, while long-term debt decreased by 0.6% to $18.3 billion [9] Share Repurchase and Guidance - Centene repurchased common shares worth $41 million in the first quarter, with a remaining capacity of $2.2 billion under its share repurchase authorization [11] - For 2025, management anticipates premium and service revenues between $164-$166 billion, indicating a growth of 13.4% from 2024 [12] - Adjusted EPS is expected to exceed $7.25, reflecting a 1.1% increase from 2024 [13]